Success Metrics

Clinical Success Rate
40.0%

Based on 2 completed trials

Completion Rate
40%(2/5)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
3(60%)

Phase Distribution

Ph phase_2
2
40%
Ph phase_1
3
60%

Phase Distribution

3

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(3)

Detailed Status

Terminated3
Completed2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
40.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (60.0%)
Phase 22 (40.0%)

Trials by Status

terminated360%
completed240%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer

NCT00450619
completedphase_1

Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer

NCT00021424
terminatedphase_1

Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy

NCT00072137
terminatedphase_2

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00087373
terminatedphase_1

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

NCT00030693

Clinical Trials (5)

Showing 5 of 5 trials
NCT00450619Phase 2

153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer

Completed
NCT00021424Phase 1

Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer

Completed
NCT00072137Phase 1

Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy

Terminated
NCT00087373Phase 2

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Terminated
NCT00030693Phase 1

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

Terminated

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5